Form 4 for MRK Merck & Co.
Accepted 2024-02-15 00:00:00 ET · period of report 2024-02-14 · accession 0001127602-24-005196 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-15 | 2024-02-14 | MRK | Litchfield Caroline | EVP, CFO | M - OptEx | $58.08 | +38.3K | 89.2K | +75% | +$2.22M |
| D | 2024-02-15 | 2024-02-14 | MRK | Litchfield Caroline | EVP, CFO | S - Sale+OE | $125.50 | -38.3K | 50.9K | -43% | -$4.81M |
| D | 2024-02-15 | 2024-02-14 | MRK | Litchfield Caroline | EVP, CFO | M - OptEx | $0.00 | -38.3K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | M | A | 38,291 | $58.08 | 89,199.19 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-14 | S | D | 38,291 | $125.50 | 50,908.19 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.5000 to $125.5050, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. (F2) Holdings include shares acquired in dividend reinvestment transactions. |
| 3 | Derivative | Stock Option (Right to Buy) | 2024-02-14 | M | D | 38,291 | $0.00 | 0 | D | $58.08 · 2016-05-01 to 2025-04-30 | 38,291 Common Stock | (F3) Exercise price and holdings reflect the adjustments that occurred as of June 2, 2021 in connection with the Organon & Co. ("Organon") spin-off as described in the registration statement on Form 10 filed with the SEC by Organon (the "Form 10"). As reported in the Form 10, all Merck stock option awards outstanding as of immediately prior to the distribution date were converted on the distribution date into adjusted Merck awards for Merck employees to preserve the same intrinsic value and general terms and conditions (including vesting) as were in place immediately prior to the adjustments. (F4) The option vested and became exercisable in equal installments on 5/1/2016, 5/1/2017 and 5/1/2018. |